Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Participants with chronic renal failure on hemodialysis for ≥ 3 months prior to randomization.~2. On intravenous epoetin alfa maintenance therapy continuously prescribed for a minimum of 8 weeks prior to randomization.~3. Four consecutive hemoglobin values with a mean ≥ 10.0 and ≤ 12.0 g/dL during the screening period~Exclusion Criteria~1. Females who are pregnant or breast-feeding.~2. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule or to all parenteral iron supplementation products.~3. Known bleeding or coagulation disorder.~4. Known hematologic disease or cause of anemia other than renal disease~5. Poorly controlled hypertension~6. Evidence of active malignancy within one year prior to randomization.~7. Temporary (untunneled) dialysis access catheter.~8. A scheduled kidney transplant~9. A scheduled surgery that may be expected to lead to significant blood loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): None
- Epoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).